Microbial
biofilms are a major concern in wound care, implant devices,
and organ infections. Biofilms allow higher tolerance to antimicrobial
drugs, can impair wound healing, and potentially lead to sepsis. There
has been a recent focus on developing novel nanocarrier-based delivery
vehicles to enhance the biofilm penetration of traditional antibacterial
drugs. However, a feasible in vitro human skin model to mimic the
biofilm formation and its treatment for clearance have not yet been
reported. This study describes the benefits of using an innovative
bacterial biofilm-infected keratinocyte clusteroid model for the first
time. It paves a new way for testing innovative nanomedicine delivery
systems in a rapid and reproducible way on a realistic human cell-based
platform, free of any animal testing. Herein, we have developed a
novel composite 3D biofilm/human keratinocyte clusteroid coculture
platform, which was used to measure biofilm clearance efficiency of
nanoparticle (NP)-based therapeutics. We tested this model by treating
the biofilm-infected 3D coculture layers by a ciprofloxacin-loaded
Carbopol nanogel particles, surface-functionalized by the cationic
protease Alcalase. We measured the antibacterial efficiency of the
NP treatment on clearing Staphylococcus aureus and Pseudomonas aeruginosa biofilms
on the 3D keratinocyte clusteroid/biofilm coculture model. Our experiments
showed that these bacteria can infect the 3D layer of keratinocyte
clusteroids and produce a stable biofilm. The biofilms were efficiently
cleared by treatment with a formulation of 0.0032 wt % ciprofloxacin-loaded
in 0.2 wt % Carbopol NPs surface-functionalized with 0.2 wt % Alcalase.
Taken together, these promising results demonstrate that our coculture
model can be exploited as a novel platform for testing the biofilm-eliminating
efficiency of various NP formulations emulating skin and wound infections
and could have wider applicability to replace animal models in similar
experiments. This 3D cell culture-based platform could help in developing
and testing of more effective antibacterial agents for clinical applications
of antiplaque dental treatments, implants, infection control, and
wound dressings.